All News

hidradenitis.jpg

ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes

d Jack Cush, MD

Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include pyoderma gangrenosum, acne and suppurative hidradenitis, Pyogenic Arthritis, Pyoderma gangrenosum and Acne, pyogenic arthritis, PG, acne and suppurative hidradenitis, and Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis, amongst others.

Read Article
Leflunomide

ICYMI: 9 Facts about Leflunomide

d Jack Cush, MD

Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. Here are some highpoints from this Medscape article and lecture.

Read Article
heel enthesitis spur calcaneal

ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis

d Jack Cush, MD

An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA).

Read Article
MRI.kneepain.jpg

ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update

d Jack Cush, MD

EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).

Read Article
Malar,rash,SLE, Lupus

ICYMI: JAMA: SLE Review

d Jack Cush, MD

Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.

Read Article
guidelines.jpg (keep)

ICYMI: BSR Guideline on Management of Sjogren’s Syndrome

d Jack Cush, MD

Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficient interventions for those affected with mucosal or systemic manifestations. The British Society of Rheumatology has updated its 2017 guidelines, with wider evidence and recommendations for the management of children and adolescents with SD. This article reviews the data and recommendations stemming from 19 questions on SD care.

Read Article
RT @yuz6yusof #EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare

Dr. John Cush RheumNow ( View Tweet)

10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab. #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

Review of Amyloidosis The New England Journal of Medicine has published a review of systemic amyloidosis. https://t.co/4507N4DwLk https://t.co/Q0MP5XXUHr

Links:

Dr. John Cush RheumNow ( View Tweet)
Future Big BiTEs (6.28.2024) Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on https://t.co/V10S4oVFsv. https://t.co/AKb2qmQ2nf https://t.co/3nKuEXteXS

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @drminidey OP0165- incidence & risk factors of D2T RA in an early RA cohort Factors assoc with D2T RA: 🩸 Seropositivity 🦴 Erosions 📈 Disease activity 📊 D2T pts have higher steroid doses & more commonly develop iatrogenic-related #comorbidities, e.g. osteoporosis

Dr. John Cush RheumNow ( View Tweet)

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US. The US FDA has also approved 2 other biosimilars to ustekinumab, including ustekinumab-aekn (Selarsdi) and ustekinumab-auub (Wezlana). https://t.co/BgYQm39aEB https://t.co/XZhnHxPaP0

Links:

Dr. John Cush RheumNow ( View Tweet)
How do you manage new progressive ILD?

Dr. John Cush RheumNow ( View Tweet)

RT @drdavidliew "We’ve got better at treating RA over the last 20 years, and it’s genuinely saving lives. Something to be very proud of. Let’s not forget that! 5y mortality from DANBIO (still, we still have work to do in seropos RA in men!) #EULAR2024 OP0162

Dr. John Cush RheumNow ( View Tweet)

RT @drdavidliew "I’ve always thought new RA meds get prescribed to the most risky patients, and therefore you see more adverse events. Turns out it’s marginally true - maybe out to five years. Worth being careful of judging new meds too early! #EULAR2024 OP0114 @karolinskainst

Dr. John Cush RheumNow ( View Tweet)

Imaging in Axial Spondyloarthritis Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria. https://t.co/SqTi4Xvoo2 https://t.co/TzZdUEkOXW

Links:

Dr. John Cush RheumNow ( View Tweet)
Axial & Psoriatic Disease Dr. Peter Nash at Eular 2024 in Vienna, Austria. https://t.co/eHfNQgN1BQ https://t.co/Uj6AwbXj8J

Links:

Dr. John Cush RheumNow ( View Tweet)
Factors Affecting Hydroxychloroquine Adherence A study from the University of British Columbia has evaluated the trajectories of HCQ use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence. https://t.co/kDUxVCfRGt https://t.co/1v79Vqdqo8

Links:

Dr. John Cush RheumNow ( View Tweet)
No Risk of Interstitial Lung Disease with Methotrexate Use JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM). https://t.co/qauRelAkG0 https://t.co/bhSLYrfzlv

Links:

Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/yyayyPcN9L https://t.co/4IQfmvbg4G

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×